PFG
AUPH icon

Piershale Financial Group’s Aurinia Pharmaceuticals AUPH Stock Holding History

Piershale Financial Group’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$1.45K Hold
150
– – ﹤0.01% 237
2023
Q1 		$1.64K Hold
150
– – ﹤0.01% 254
2022
Q4 		$648 Buy
+150
New +$870 ﹤0.01% 285

Other funds holding AUPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Piershale Financial Group's AUPH Position: Q2 2023 in Review

Piershale Financial Group held its Aurinia Pharmaceuticals (AUPH) position steady in Q2 2023 at 150 shares worth $1.45K. The position accounts for ﹤0.01% of the portfolio, ranked #237.

Piershale Financial Group first reported a position in AUPH in Q4 2022 and has held it in 3 quarters since. The position peaked at $1.64K in Q1 2023. 200 funds tracked by Wall St. Rank hold AUPH as of Q2 2023.

  • Piershale Financial Group held 150 shares of Aurinia Pharmaceuticals worth $1.45K as of Q2 2023.
  • Piershale Financial Group left its Aurinia Pharmaceuticals share count unchanged in Q2 2023.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Piershale Financial Group's portfolio in Q2 2023, its #237 holding.
  • Piershale Financial Group first reported a position in Aurinia Pharmaceuticals in Q4 2022 and has held it in 3 quarters since.
  • Piershale Financial Group's Aurinia Pharmaceuticals position peaked at $1.64K in Q1 2023.
  • 200 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2023.

Based on Piershale Financial Group's 13F filing for Q2 2023, filed 6 Jul 2023.